Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Non-Current Debt (2020)

Foghorn Therapeutics (FHTX) has 1 years of Non-Current Debt data on record, last reported at $19.7 million in Q4 2020.

  • For Q4 2020, Non-Current Debt changed N/A year-over-year to $19.7 million; the TTM value through Dec 2020 reached $19.7 million, changed N/A, while the annual FY2020 figure was $19.7 million, N/A changed from the prior year.
  • Non-Current Debt reached $19.7 million in Q4 2020 per FHTX's latest filing, up from $8.8 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $19.7 million in Q4 2020 and bottomed at $8.8 million in Q3 2020.